Good News | Azvudine is Honored with the "Best Commercial Return Award"

The "2024 China Biopharmaceutical Industry Chain Innovation Billboard" was officially announced during the Sixth Session China Biopharmaceutical Industry Innovation and Transformation International Summit & the First Guangdong-Hong Kong-Macao Greater Bay Area Biopharmaceutical Industry Innovation and Transformation Forum, grandly held in Guangzhou on December 17, 2024. Azvudine, independently developed by Genuine Biotech, was honored with the "Best Commercial Return Award (Chemical Drug)" for its outstanding performance during its three years on the market.

Azvudine, an innovator drug in China, is a Class 1.1 innovative drug with fully independent intellectual property rights and was awarded the Golden Medal of China Patent Award. As the world's only dual-target (reverse transcriptase and viral infectivity factor) nucleoside oral drug for the treatment of HIV infection, Azvudine was approved for the indication of HIV-1 in Jul. 2021. In Jul. 2022, Azvudine was approved for marketing for the treatment of COVID-19. It is the first domestic oral drug approved for the treatment of COVID-19 in China, and has been included in the diagnosis and treatment protocol for COVID-19 patients of China several times, curing more than ten million patients. After being approved for marketing for the treatment of COVID-19 in 2022, Azvudine has been rapidly included in the basic medical insurance networks across 31 provinces, autonomous regions, and municipalities of China, covering over 50,000 medical institutions, making it the drug with the widest hospital coverage in the country so far. Both indications have been successfully renewed in the 2024 National Reimbursement Drug List recently.

The selection of the "China Biopharmaceutical Industry Chain Innovation Billboard" is initiated by the China Biopharmaceutical Industry Innovation and Transformation Alliance (CBIITA). Since its inception in 2020, it has been consecutively held for 5 years, always adhering to the purpose of "Establishing Industry Benchmarks, Fostering Innovation Potential, and Nurturing Foundation for Innovation". The selection process combines objective data with expert insights by analyzing and validating from different perspectives. Each award ceremony is witnessed by a distinguished assembly of Chinese and foreign academicians, leaders from relevant divisions of national ministries, representatives of national scientific associations, experts from academic research institutes and clinical trial institutions, investment partners, as well as executives from listed and pre-listed enterprises. It has become a benchmark award in the field of biopharmaceutical industry innovation and transformation.